Neurology / Drugs / Therapeutics / Drug / Boston / Boston blog main / Boston top stories / National blog main / Adam Rosenberg / Alzheimer's / Annovation BioPharma / Arteaus Therapeutics / Atlas Venture / Biogen / Biotech / Celgene / deals / Eli Lilly / frontotemporal dementia / google / HDAC / Life Sciences / Novartis / Parkinson's / Proteon Therapeutics / Quanticel Pharmaceuticals / Rodin Therapeutics / startups / The Medicines Co. / VC

After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial

Posted on: Sep 18, 2017   |   Posted by: Biotech Mag

After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial

An option-to-buy deal, when one company agrees to buy another on prearranged terms after a series of milestones are met, doesn't always lead to an acquisition. Sometimes, as...

Continue reading ...